Press Releases

September 28, 2017
NOHLA THERAPEUTICS AWARDED $6.9 MILLION GRANT FROM THE CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE TO FURTHER DEVELOP NLA101 CELL THERAPY FOR THE TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
DOWNLOAD PDF

May 16, 2017
NOHLA THERAPEUTICS PRESIDENT AND CEO, KATIE FANNING, TO PRESENT AT 2017 LIFE SCIENCE INNOVATION NORTHWEST CONFERENCE
DOWNLOAD PDF

March 28, 2017
NOHLA THERAPEUTICS ANNOUNCES COLLABORATION WITH UNIVERSITY OF CALIFORNIA, DAVIS TO OPTIMIZE MANUFACTURING PROCESS AND SUPPLY CELL THERAPY PRODUCT FOR CLINICAL TRIALS
DOWNLOAD PDF

February 14, 2017
NOHLA THERAPEUTICS TO PRESENT AT THE COWEN AND COMPANY 37TH ANNUAL HEALTH CARE CONFERENCE ON MARCH 7TH, 2017
DOWNLOAD PDF

February 8, 2017
GOVERNOR JAY INSLEE LEADS RIBBON CUTTING CEREMONY AT NOHLA’S SEATTLE HEADQUARTERS
DOWNLOAD PDF

February 2, 2017
NOHLA THERAPEUTICS APPOINTS KATHLEEN FANNING AS PRESIDENT AND CHIEF EXECUTIVE OFFICER
DOWNLOAD PDF

November 30, 2016
NOHLA THERAPEUTICS APPOINTS SHELLY HEIMFELD, PH.D., EXECUTIVE VICE PRESIDENT OF RESEARCH AND MANUFACTURING
DOWNLOAD PDF

November 29, 2016
NOHLA THERAPEUTICS ANNOUNCES CLOSING OF $43.5M SERIES A FINANCING TO TRANSFORM STEM CELL TRANSPLANTATION WITH INNOVATIVE OFF THE SHELF, UNIVERSAL DONOR CELLULAR THERAPY
DOWNLOAD PDF

October 19, 2016
NOHLA THERAPEUTICS SIGNS EXCLUSIVE SUPPLY AGREEMENT WITH LIFESOUTH COMMUNITY BLOOD CENTERS
DOWNLOAD PDF

December 23, 2015
NOHLA THERAPEUTICS CLOSES OVERSUBSCRIBED US$21M PRIVATE FINANCING ROUND AND STRENGTHENS BOARD WITH NEW APPOINTMENT
DOWNLOAD PDF

December 3, 2015
NOHLA THERAPEUTICS LAUNCHES WITH MAJOR US CANCER RESEARCH INSTITUTE DEAL, SUBSTANTIAL INVESTMENT ROUND, AND KEY APPOINTMENTS
DOWNLOAD PDF

JULY 16, 2018
NOHLA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR DILANUBICEL FOR HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
DOWNLOAD PDF

JULY 11, 2018
NOHLA THERAPEUTICS ANNOUNCES SECOND CLOSING OF $56 MILLION SERIES B FINANCING
DOWNLOAD PDF

JUNE 15, 2018
NOHLA ANNOUNCES PRESENTATION OF DILANUBICEL (NLA101) DATA AT EHA SHOWCASING EXCELLENT LONG-TERM SURVIVAL OUTCOMES
DOWNLOAD PDF

JUNE 6, 2018
NOHLA RECEIVES EMA PRIME DESIGNATION FOR DILANUBICEL (NLA101) TO TREAT HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
DOWNLOAD PDF

May 17, 2018
NOHLA THERAPEUTICS ANNOUNCES EHA ABSTRACT ACCEPTANCE ON DILANUBICEL (NLA101) OFF-THE-SHELF CELL THERAPY SHOWING EXCELLENT LONG-TERM SURVIVAL OUTCOMES
DOWNLOAD PDF

May 15, 2018
NOHLA THERAPEUTICS ANNOUNCES CLOSING OF $45 MILLION SERIES B FINANCING
DOWNLOAD PDF

April 23, 2018
NOHLA THERAPEUTICS ANNOUNCES HIRING OF GARY CHRISTIANSON AS CHIEF OPERATING OFFICER
DOWNLOAD PDF

March 21, 2018
NOHLA THERAPEUTICS SELECTS ADVANCED THERAPIES BUSINESS UNIT OF WUXI APPTEC TO MANUFACTURE UNIVERSAL DONOR CELL THERAPIES
DOWNLOAD PDF

February 13, 2018
NOHLA THERAPEUTICS INITIATES GLOBAL LAUNCH PHASE 2 TRIAL OF NLA101 IN PATIENTS WITH AML
DOWNLOAD PDF

January 23, 2018
NOHLA THERAPEUTICS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR NLA101 IN THE TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
DOWNLOAD PDF

January 4, 2018
NOHLA THERAPEUTICS ANNOUNCES HIRING OF JIM JOHNSON AS CHIEF FINANCIAL OFFICER
DOWNLOAD PDF